id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_s7b2jt5babfl5lvpbil25sfp5i	Lida A. Mina	A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109	2013	4	.pdf	application/pdf	2895	287	55	bevacizumab and sorafenib in patients with metastatic breast bevacizumab and sorafenib in patients with metastatic breast There were no complete or partial responses; 3 patients had stable disease for >6 months. VEGF inhibition with sorafenib and bevacizumab in pretreated patients with advanced breast cancer. This report summarizes the results of the study of the combination of Sorafenib with Bevacizumab in previously treated patients with metastatic breast cancer. Sunitinib and bevacizumab was tried in patients with advanced renal cell carcinoma, again significant toxicity was complete remission following combination chemotherapy for metastatic breast cancer. evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) phase I trial of sorafenib (S) and bevacizumab (B) in patients Feldman DR et al (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.	./cache/work_s7b2jt5babfl5lvpbil25sfp5i.pdf	./txt/work_s7b2jt5babfl5lvpbil25sfp5i.txt